Hypofractionated radiotherapy for prostate cancer in a Latin American Hospital: quality of life and toxicity

Hypofractionated radiotherapy for prostate cancer in a Latin American Hospital: quality of life and toxicity

Andrea C. Araujo 1 , Juan G. Cataño 2 , Alejandro González-Motta 3 , Juan C. Galvis 3 , Andrés F. Gutiérrez 4 , Santiago Rodriguez 2 , Martín A. Rondón 5

1 Department of Urology, Pontificia Universidad Javeriana, Bogotá D.C., Colombia; 2 Department of Urology, Urologic Oncology, Functional Unit of Genitourinary Tumors and Prostate Cancer, Hospital Universitario San Ignacio, Bogotá D.C., Colombia; 3 Department of Radiation Oncology, Hospital Universitario San Ignacio, Bogotá D.C., Colombia; 4 Department of Urology, Urologic Oncology, Fundación Santa Fe de Bogotá, Bogotá D.C., Colombia; 5 Department of Clinical Epidemiology and Biostatistics, Pontificia Universidad Javeriana, Bogotá D.C., Colombia

*Correspondence: Andrea C. Araujo. Email: andreaaraujo2707@gmail.com

Abstract

Objective: To evaluate acute and late genitourinary and gastrointestinal toxicity, as well as quality-of-life outcomes, in patients with localized prostate cancer treated with hypofractionated radiotherapy in a Latin American population, given that optimal fractionation for radiotherapy remains under debate and there is a lack of regional evidence describing these outcomes. Method: A prospective cohort study was performed. Patients with localized prostate cancer treated with hypofractionated radiotherapy at the Centro Javeriano de Oncología were included. The main outcome was acute and late genitourinary and gastrointestinal toxicity at 14 days, 3 months, and 1 year. Sexual, bowel, and urinary quality of life was assessed at 3 months, 6 months, and 1 year after completion of radiotherapy. Results: One hundred and seventy-six patients were included. The overall quality of life in physical score showed a decrease at 6 months, while at 3 months and 1 year, no differences were found. In the mental score, no differences were found at any cut-off point, likewise for the quality of life by domains. Regarding urinary and rectal toxicity, both acute and late, no differences were found in any case. Conclusions: Our study shows that there are no relevant negative impacts in terms of general and domain-specific quality of life, as well as for acute and late genitourinary and gastrointestinal toxicity up to 1 year of follow-up, with promising results in terms of oncologic outcomes.

Keywords: Prostate cancer. Radiation therapy. Radiation dose hypofractionation. Dose fractionation. Radiation.

Contents

The full content will be available shortly. Thank you for your patience!